For example, studies have demonstrated that CTCs may escape EpCAM-based detection due to the epithelial-mesenchymal transition [60], often a prominent feature of PDACs, and there are many reports for various types of cancers where EpCAM-negative CTCs have been described (e.g. breast cancer; [61,62]). This evidence concerns the gene EPCAM and breast cancer.